89bio, Inc. - Common Stock (ETNB)

Competitors to 89bio, Inc. - Common Stock (ETNB)

Acorda Therapeutics

Acorda Therapeutics focuses on developing innovative therapies for neurological diseases, which overlaps with 89bio's focus on metabolic liver diseases. Both companies are in the biotechnology sector and aim to address unmet medical needs, giving them similar target markets. However, Acorda has a more established portfolio and greater clinical experience, providing it with a slight edge in credibility and investor confidence.

Eledon Pharmaceuticals 

Eledon Pharmaceuticals develops therapies for kidney and liver diseases, overlapping with 89bio's market focus. While both firms are targeting metabolic diseases, Eledon has concentrated efforts and successful partnerships in related therapeutic areas, which could provide it with leverage in negotiations and funding. This strategic positioning potentially grants Eledon a competitive advantage over 89bio.

Galmed Pharmaceuticals 

Galmed Pharmaceuticals specializes in the development of therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH), making it a direct competitor to 89bio. Both companies are engaged in addressing similar patient needs, but Galmed has advanced further in clinical trials for its lead product candidate, giving it a potential competitive advantage in accessing the market first.

Interregenesis

Interregenesis is engaged in the development of therapies targeting metabolic and immunological disorders, similar to 89bio's focus on liver diseases. The companies compete for research funding and partnerships within the pharmaceutical industry. Interregenesis has a diversified pipeline that gives it a broader range of potential funding and collaboration opportunities, which could represent a competitive advantage over 89bio.

Madrigal Pharmaceuticals 

Madrigal Pharmaceuticals focuses primarily on NASH and other liver diseases, making it one of 89bio's significant competitors. Both companies aim to bring new treatments to market in a competitive therapeutic area, but Madrigal's late-stage clinical trials and stronger financial backing provide it a competitive advantage over 89bio in terms of development pace and market positioning.